Armis Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Armis Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	+1,528	New	+$207K	0.02%	411

Other funds holding XBI

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Armis Advisers's XBI Position: Q2 2026 in Review

Armis Advisers opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 1,528 shares worth $246K. The stake represents 0.02% of the portfolio and ranks #411 among its holdings.

157 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Armis Advisers held 1,528 shares of State Street SPDR S&P Biotech ETF worth $246K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Armis Advisers position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.02% of Armis Advisers's portfolio in Q2 2026, its #411 holding.
157 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Armis Advisers's 13F filing for Q2 2026, filed 7 Jul 2026.